Geode Capital Management LLC increased its holdings in shares of Shire (NASDAQ:SHPG) by 7.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,724 shares of the biopharmaceutical company’s stock after buying an additional 3,578 shares during the quarter. Geode Capital Management LLC’s holdings in Shire were worth $8,333,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. Boston Partners grew its stake in Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after purchasing an additional 886,572 shares in the last quarter. ING Groep NV boosted its stake in shares of Shire by 9,043.1% during the 4th quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock worth $81,366,000 after acquiring an additional 518,800 shares in the last quarter. Sterling Capital Management LLC boosted its stake in shares of Shire by 26,182.4% during the 3rd quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock worth $72,649,000 after acquiring an additional 472,592 shares in the last quarter. FNY Partners Fund LP boosted its stake in shares of Shire by 346.6% during the 4th quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock worth $73,598,000 after acquiring an additional 368,214 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Shire by 362.8% during the 4th quarter. Bank of Montreal Can now owns 182,904 shares of the biopharmaceutical company’s stock worth $28,373,000 after acquiring an additional 143,385 shares in the last quarter. Institutional investors and hedge funds own 19.58% of the company’s stock.
Shares of SHPG opened at $162.54 on Thursday. The firm has a market capitalization of $47,130.30, a price-to-earnings ratio of 10.24, a PEG ratio of 1.22 and a beta of 1.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.55 and a current ratio of 0.97. Shire has a 52 week low of $123.73 and a 52 week high of $192.15.
Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. The firm had revenue of $4.14 billion for the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.37 earnings per share. analysts forecast that Shire will post 15.22 EPS for the current year.
The company also recently disclosed a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be given a $0.8937 dividend. This represents a yield of 1.33%. This is a positive change from Shire’s previous semiannual dividend of $0.15. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s dividend payout ratio (DPR) is presently 6.93%.
Several analysts have recently issued reports on the company. Piper Jaffray reiterated a “hold” rating on shares of Shire in a research note on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research cut Shire from a “hold” rating to a “sell” rating in a research report on Monday, April 9th. Liberum Capital reissued a “hold” rating on shares of Shire in a research report on Wednesday, December 20th. Finally, Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $203.29.
TRADEMARK VIOLATION WARNING: “Shire (NASDAQ:SHPG) Shares Bought by Geode Capital Management LLC” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/04/19/shire-shpg-shares-bought-by-geode-capital-management-llc.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.